Human Reproduction Update Advance Access originally published online on July 11, 2006
Human Reproduction Update 2006 12(5):573-584; doi:10.1093/humupd/dml031
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology of impaired ovarian function in galactosaemia
1 Department of Reproductive Medicine, Maternité Régionale Universitaire, Nancy Cedex, France, 2 Research Unit EA 4002, Université Nancy I, Vandoeuvre les Nancy Cedex and 3 Paediatric Intensive Care Unit, Hôpital Sainte Justine, Montréal, Québec, Canada
4 To whom correspondence should be addressed at: Department of Reproductive Medicine, Maternite Regionale Universitaire, 10, rue Dr Heydenreich BP74213, F-54042 Nancy Cedex, France. E-mail: t.forges{at}maternite.chu-nancy.fr
 |
Abstract |
|---|
 TOP Abstract Galactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
Classical galactosaemia is an inherited inborn error of the major galactose assimilation pathway, caused by galactose-1-phosphate uridyltransferase (GALT) deficiency. Many GALT mutations have been described, with different clinical consequences. In severe forms, newborns present with a life-threatening, acute toxic syndrome that rapidly regresses under a galactose-restricted diet. However, long-term complications, particularly cognitive and motor abnormalities, as well as hypergonadotrophic hypogonadism in female patients are still unavoidable. The pathogenesis of galactose-induced ovarian toxicity remains unclear but probably involves galactose itself and its metabolites such as galactitol and UDP-galactose. Possible mechanisms of ovarian damage include direct toxicity of galactose and metabolites, deficient galactosylation of glycoproteins and glycolipids, oxidative stress and activation of apoptosis. As there is no aetiological treatment, clinical management of ovarian failure in galactosaemic patients principally relies on hormonal replacement therapy to induce pubertal development and to prevent bone loss and other consequences of estrogen deprivation. Further investigations will be necessary to better understand the metabolic flux of galactose through its biochemical pathways and the mechanisms of these secondary complications. The aim of this article is to present an extensive review on the pathogenesis and clinical management of galactose-induced premature ovarian failure.
Key words: apoptosis / galactitol / galactosaemia / galactose / premature ovarian failure
|
Galactose: origins and metabolism |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
The monosaccharide galactose is a hexose that differs from glucose only by the configuration of its carbon 4 hydroxyl group. Galactose has principally a dietary origin, but there is also a considerable endogenous production that has to be taken into account especially in pathological situations.
Galactose is a ubiquitously distributed sugar in animals and plants. Many fruits, vegetables and fermented nutrients contain large amounts of this hexose (Acosta and Gross, 1995
). The most common source of galactose, however, is milk and its derivatives, which contain lactose, a disaccharide formed by galactose and glucose. Cow’s milk contains 4.5–5.5% of lactose, i.e. about 23 g of galactose per litre. Lactose is cleaved into its two components, galactose and glucose, by an intestinal lactase. Both sugars are then taken up into the intestinal epithelial cells by a common transporter. On average, dietary galactose intake in industrial countries varies between 3 and 14 g of galactose per day (Cooper et al., 1994).
Endogenous galactose essentially originates from the transformation of glucose and additionally comes from recycling of glycosylated proteins and lipids. The amount of endogenous galactose production has been recently readdressed in in vivo tracer studies, using 13C-galactose either by continuous i.v. infusion or by a single bolus injection (Berry et al., 2004a). By the means of these techniques, authors determined the galactose appearance rate in galactosaemics and healthy controls. They found an increased galactose production in children when compared with adults. Moreover, the galactose appearance rate and the whole-body galactose pool were significantly higher in patients than in controls, whereas galactose plasma levels in patients under diet treatment were low. This suggested the existence of some tissue pools that may be expanded with galactose. Overall, the galactose production in adult galactosaemic patients ranged from 0.42 to 0.72 mg/kg/h, i.e. around 1 g per day.
Conversion of galactose to glucose
The main metabolic pathway of galactose, the so-called Leloir pathway (Figure 1), leads to its conversion to glucose in three steps catalysed by three specific enzymes. During the first step, galactose, newly entered into the cell, is phosphorylated to galactose-1-phosphate by an ATP-dependent galactokinase (GALK; EC 2.7.1.6 [EC] ). Subsequently, a UDP group provided by UDP-glucose is transferred to galactose-1-phosphate by galactose-1-phosphate uridyltransferase (GALT; EC 2.7.7.10 [EC] ). During this step, galactose-1-phosphate is converted to UDP-galactose, while UDP-glucose is converted to glucose-1-phosphate. UDP-galactose is the indispensable donor molecule that is required for the incorporation of galactose into the carbohydrate moiety of glycoproteins and glycolipids. The third step of the Leloir pathway is the conversion of UDP-galactose to UDP-glucose by a NAD+-dependent UDP-galactose-4-epimerase (GALE; EC 5.1.3.2 [EC] ). UDP-glucose is then used again in the second step to metabolize further galactose molecules or is converted to glucose-1-phosphate by UDP-glucose pyrophosphorylase (UGP2; EC 2.7.7.9 [EC] ) with the release of UTP. Finally, glucose-1-phosphate is converted to glucose-6-phosphate by a phosphoglucomutase and moves through the glycolytic pathway and the tricarboxylic acid cycle to be oxidized to CO2.
|
This pathway allows a rapid and efficient galactose purging: studies using radiolabelled 13C-galactose given i.v. showed that 30 min after a loading dose, 50% of the injected galactose was converted to glucose (Segal and Berry, 1995
). Alternative galactose catabolism
Direct evidence for the functional importance of alternative pathways came from the study of a patient in whom 10 of the 11 GALT exons were deleted, and thus no residual GALT activity could remain (Berry et al., 2001b). By measuring radiolabelled 13C-CO2 in the expired air after oral administration of 13C-galactose, it was shown that this patient oxidized 17% of the initial dose of galactose to CO2 within 24 h. This amount was as much as healthy controls usually metabolize within 3 h. Further studies confirmed a similar but considerably delayed galactose-oxidizing capacity in galactosaemics, when compared with controls (Berry et al., 2004b). Three alternative pathways have been identified (Figure 1).
First, galactose may be metabolized by reduction to galactitol. This reaction is principally catalysed by ADP+-dependent aldose reductase (EC 1.1.1.21
[EC]
), which converts sugars to their corresponding polyols. Galactitol is not further catabolized and is excreted in urine. The importance of this reaction in blocked Leloir pathway is illustrated by high serum and urine galactitol concentrations in galactosaemic patients, even under a strict galactose-free diet (Segal and Berry, 1995).
Second, galactose may be oxidized by galactose dehydrogenase to galactonate which is further converted to D-xylulose with the release of CO2. Thereafter, D-xylulose can enter the pentose-phosphate cycle. Radiolabelled tracer studies proved this oxidation to be effective in patients with a blockage in the Leloir pathway but to a much lesser extent when compared with galactitol production. Nevertheless, it is a way to slowly metabolize small amounts of ingested or endogenously produced galactose (Segal, 1998).
Third, part of the galactose-1-phosphate that accumulates in case of a blockage of the Leloir pathway can react with UTP to form UDP-galactose and pyrophosphate. This reaction is catalysed by UGP2 (UDP-glucose pyrophosphorylase) and yields part of the UDP-galactose required for galactosylation. This pathway has been analysed in transgenic yeast overexpressing UGP2 (Lai and Elsas, 2000) and is also functioning in humans. Probably the resulting UDP-glucose is first converted to glycogen which is subsequently hydrolysed to glucose-1-phosphate which then enters the glycolytic pathway to be oxidized to CO2. It has been hypothesized that the delayed galactose oxidation in galactosaemics may be due to this detour (Segal et al., 2006).
|
Pathology of galactose metabolism |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
Three inborn errors of galactose metabolism are known, i.e. one for each enzyme deficiency involved in the Leloir pathway. All of them are autosomal recessive disorders. GALK deficiency is a very rare disease caused by non-sense mutations within the GALK gene, with clinical features limited to neonatal or early adult cataract (Novelli and Reichardt, 2000
; Bosch et al., 2002). GALE deficiency is caused by mutations in the GALE gene and classically presents as either a peripheral form, with deficient enzyme activity only in red and white blood cells and an absence of abnormal phenotype, or a generalized form, as described in some neonates, principally in cases of parental consanguinity, with clinical signs resembling GALT deficiency (Novelli and Reichardt, 2000). More recently, the existence of intermediate forms with partial enzyme activities reaching from 15 to 64% of normal has been put forward, suggesting that this deficiency is a continuous rather than a binary disease (Openo et al., 2006). However, the most frequent inborn error of the Leloir pathway is GALT deficiency, also called classical galactosaemia. In cases of a complete or nearly complete GALT deficiency, a severe hepatic and renal failure develops in the neonate and finally leads to death when untreated. In many countries, galactosaemic newborns are discovered either through mass screening or early in the clinical course. When a galactose-free diet is instituted in time, acute symptoms disappear promptly, but nevertheless long-term complications including ovarian dysfunction will appear in most patients. In the following, the term galactosaemia will refer to this GALT deficiency, if not otherwise specified. Clinical and biological features of classical galactosaemia
Classical galactosaemia is caused by mutations in the GALT gene located on chromosome 9p13 (Leslie et al., 1992). Over 180 mutations, mostly nucleotide substitutions, have been described (Bosch et al., 2005); among those, the Q188R mutation, characterized by the replacement of glutamine by arginine at position 188, is detected in over 70% of galactosaemics in Europe and North America, where the incidence of the disease is 
1:30 000, and determines a severe neonatal phenotype in untreated homozygotes. In the African and African-American populations, the S135L mutation is predominant and leads to a much less severe phenotype (Segal and Berry, 1995). A further common mutation, N314D, which is occuring in all of these populations, leads to two different phenotypes. In some cases (the so-called Los Angeles type), where the N314D mutation is associated with a neutral polymorphism at leucine 218, GALT activity is increased (Langley et al., 1997). In other cases (the Duarte type), where the N314D mutation is associated with a four-nucleotide deletion in the promoter region, a 50% decrease of GALT activity is observed, resulting in a mild or even undetectable clinical phenotype (Elsass et al., 2001). A few cases with large deletions in the GALT gene, and thus no residual GALT activity at all, have also been described (Berry et al., 2001b; Bosch et al., 2005).
Classical galactosaemia is a complex, life-threatening condition occurring during the first weeks of life and includes various clinical abnormalities (Table I) which, in the absence of a galactose-restricted diet, lead to liver failure in the second half of the first week of life and death by acute liver and kidney failure within a few days (Segal and Berry, 1995). In some cases presenting with a milder phenotype, the diagnosis will be made later in childhood when mental retardation, cataract and hepatomegalia will be detected. In other cases, galactosaemia might be completely asymptomatic, when a sufficient residual GALT activity is still maintained. Biological features include various anomalies of galactose metabolism, such as elevated plasma galactose, erythrocyte galactose-1-phosphate, galactitol and galactonate levels, as well as increased urinary excretion of these metabolites. The diagnostic and prognostic value of these molecules has been reviewed elsewhere (Segal and Berry, 1995). A special emphasis has to be given on the measurement of total galactose oxidation capacity, using radiolabelled galactose which, after i.v. or oral administration and oxidation, gives rise to radiolabelled CO2 that can be quantified in the expired air during a given time after the load (Segal and Berry, 1995; Leslie, 2003).
|
Long-term prognosis of classical galactosaemia
Once classical galactosaemia has been diagnosed, dietary galactose intake has to be avoided indefinitely by replacing human or cow’s milk by galactose-free substitutes that usually contain soybean milk. Afterwards, high-galactose-containing products, particularly dairy products and some fruits and vegetables, such as tomatoes, kiwis, nuts, have to be excluded from the diet of these patients. Whereas a restricted galactose diet allows a rapid clinical improvement of the acute galactose toxicity in the neonate, it will not fully prevent the development of long-term complications (Table I), especially growth retardation and neurological problems in both sexes, such as cognitive impairment, speech difficulties, progressive ataxia and tremor (Ridel et al., 2005) as well as gonadal failure in females. Interestingly, these delayed complications are not correlated with the time of diagnosis, the beginning of the treatment or the dietary compliance of patients (Segal and Berry, 1995).
|
Ovarian dysfunction in classical galactosaemia |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
The impairment of ovarian function in classical galactosaemia has been known for over 25 years (Kaufman et al., 1979
). Clinically, patients present with hypergonadotrophic hypogonadism in a context of either primary amenorrhoea with pubertal retardation or secondary amenorrhoea which may start at any age and progress to premature ovarian failure (POF). However, as in other aetiologies of POF, the ovarian dysfunction of galactosaemia may present transiently as a gonadotrophin-resistant ovary syndrome characterized by an alternation of periods with hypergonadotrophic failure and ovulatory cycles (Twigg et al., 1996). Therefore, the chance of a spontaneous pregnancy cannot be completely ruled out during this initial phase of ovarian failure in galactosaemic patients.
The progressive nature of ovarian failure in galactosaemia is further illustrated by the description of a histologically normal ovary in a galactosaemic girl who died at the age of 5 days (Levy et al., 1984), whereas laparoscopic ovarian biopsies performed in adolescent or adult galactosaemic women usually show a severe follicular depletion, with only a very few, and most often atretic follicles within a fibrous ovarian stroma (Kaufman et al., 1989). This is also consistent with another laparoscopic observation of morphologically normal ovaries in a 7-year-old girl, whereas 10 years later a second laparoscopy showed complete regression of her ovaries, with an aspect of streak gonads (Kaufman et al., 1981). In a few case reports of hypergonadotrophic ovarian failure in galactosaemic patients, the persistence of primordial follicles, consistent with a resistant ovary syndrome, has been described (Russell et al., 1982; Fraser et al., 1986).
How to evaluate the risk of POF in galactosaemic patients?
Retrospective analyses of a large number of patients showed that ovarian failure occurs in 75–96% of homozygous galactosaemic women (Waggoner et al., 1990). Some authors tried to identify correlations between the mutational genotype and the ovarian phenotype of these patients. Most of them agree that mutations that completely abolish GALT activity, such as the homozygous Q188R mutation, are responsible for a poor prognosis, whereas mutations which allow a residual GALT activity are less likely to induce long-term complications (Tyfield, 2000). Conversely, there has been no correlation between genotype and ovarian damage in a small series of 22 patients, but in that study the comparison concerned only the primary or secondary nature of patients’ amenorrhoea (Kaufman et al., 1994).
A recent study included 53 patients with a residual GALT activity of less than 1% (Guerrero et al., 2000). Patients were aged between 1 and 37 years; signs of ovarian failure were detected in 77% of them, and 85% of the prepubertal girls presented with elevated serum FSH levels. This study showed that the prevalence of ovarian failure was correlated neither with the age of diet onset nor with the maximal erythrocyte galactose-1-phosphate levels. However, the presence of a homozygous Q188R mutation was associated with a 16-fold increased risk of POF. It has to be taken into account, however, that this mutation is the most prominent one in the Caucasian population. Furthermore, the galactose-oxidizing capacity, measured by the 13CO2 content in the expired air, after oral uptake of 13C-labelled galactose, has been shown to predict the risk of POF, as all patients, who had eliminated less than 5% of the initial dose of 13C after 120 minutes, presented with some degree of ovarian failure. Finally, the mean level of erythrocyte galactose-1-phosphate was higher in POF patients than in patients with normal ovarian function. However, this parameter remains controversial (Kaufman et al., 1988), because galactose metabolism probably has different characteristics in red blood cells and in other tissues. In fact, it has been reported that in patients with a homozygous S135L mutation, the most frequent one in the black population, GALT activity is nearly absent in erythrocytes, whereas a residual activity is still detected, with 5% of normal activity in leukocytes and 10% in hepatocytes (Lai et al., 1996; Landt et al., 1997).
Despite the high prevalence of POF in galactosaemic patients, several cases of spontaneous pregnancies have been described, predominantly in black women who generally present with less severe forms of galactosaemia (Roe et al., 1971; Waggoner et al., 1990). More recently, an uneventful pregnancy has been reported in a 30-year-old compound heterozygous patient (de Jongh et al., 1999), and another patient with a homozygous Q188R mutation had two normal pregnancies, at the age of 20 and 22 years, respectively (Briones et al., 2001). A further, 18-year-old, Q188R-homozygous patient first experienced a triplet pregnancy with the birth of three healthy newborns and subsequently developed hypergonadotrophic amenorrhoea. Nevertheless, a second, singleton pregnancy occurred, and she delivered a fourth healthy newborn (Kimonis, 2001). This observation further illustrates the reversible character of POF during the first months or even years.
In the latter cases, it has been shown that despite the continuation of a strict diet, maternal erythrocyte galactose-1-phosphate levels increased during pregnancy. An increase was also seen in the levels of galactitol in maternal serum and, particularly, in amniotic fluid as well as in the fetal cord serum, which indicates that this metabolite crosses the placental barrier without damaging the heterozygous fetus (de Jongh et al., 1999; Briones et al., 2001).
Ovarian function in heterozygous patients
The high prevalence of ovarian failure in patients with homozygous galactosaemia has led to the hypothesis that heterozygous women, although without any clinical phenotype, may also have some minor degree of ovarian dysfunction, because of a lower GALT activity. In a study including 104 patients who were divided into two groups according to their age at menopause, before or after 48 years, authors showed that a low erythrocyte GALT activity was associated with a 14-fold increase risk of presenting with menopause before the age of 48, when compared with patients with normal GALT activity. Moreover, in patients with a heterogeneous GALT mutation, menopause occurred on average 5 years earlier than in the control group. Finally, infertility was three times more frequent in patients with a heterogeneous GALT mutation (Cramer et al., 1989a). However, the patient number in that study was too small to allow any significant statistical comparison. The same authors also described significantly higher serum FSH levels in patients heterozygous for the Q188R mutation or the Duarte variant (Cramer et al., 1994a).
Other authors did not find any correlation either between GALT activity and time to pregnancy or infertility or between the presence of a heterozygous GALT mutation and prevalence of POF (Herrinton et al., 1996). Mothers of 108 homozygous galactosaemic patients, who were all heterozygous, had 2.3 children on average and no signs of an early-onset menopause (Kaufman et al., 1993). The results of this study were globally consistent with those from another team who did not find any increased risk of infertility or spontaneous pregnancy loss in a group of women having a galactosaemic child (Sayle et al., 1996). However,that study did not take into account any infertile patients who never conceived. Nevertheless, the screening for heterogeneous GALT mutations did not yield an abnormally high frequency of these mutations among patients with known POF (Hagenfeldt et al., 1989; Kumar et al., 2005; Mlinar et al., 2005) or with infertility (Lukac Bajalo et al., 2005).
Ovarian function and galactose intake
A possible effect of high galactose consumption has also been hypothesized by several authors.
In a study including 295 women aged 38–49 years who answered to a questionnaire about nutritional habits, it was shown that women whose galactose consumption exceeded 6 g per day had significantly higher serum FSH levels than women who consumed less galactose-containing nutrients (Cooper et al., 1994). In an epidemiological approach, (Cramer et al. (1994c) investigated the persistence of intestinal lactase activity in adult individuals of different ethnic origins. Whereas in certain subjects (called lactose absorbers) this enzyme keeps on functioning throughout life, in others it loses its activity during childhood and adolescence, inducing a progressively appearing intolerance to dairy products, called adult-type hypolactasia. The persistence of lactase is an autosomal dominant trait with a high prevalence in Australia, North America and Northern Europe and a low frequency in South America, Southeast Asia and the Middle East (Simoons, 1978). The authors showed that in each of these regions the decline in female fertility between 30 and 40 years was correlated with the prevalence of persisting intestinal lactase activity and the amount of milk consumption (Cramer et al., 1994c). These are, however, only indirect arguments, and the relationship between galactose intake and fertility still needs further investigation.
Ovarian cancer and galactose intake
The hypothesis of a possible impact of galactose consumption on the risk of ovarian cancer was initially suggested by Cramer (1989), who described a positive correlation between the per capita milk consumption as well as the persistence of intestinal lactase activity and the incidence of ovarian cancer in 27 countries. In a further study, this author showed that ovarian cancer patients consumed more dairy foods and presented with a lower erythrocyte GALT activity when compared with healthy controls (Cramer et al., 1989b). A higher proportion of lactose absorbers have also been described in a small series of Sardinian ovarian cancer patients (Meloni et al., 1999). Similarly, a higher prevalence of the Duarte variant, which is generally associated with a lower GALT activity, was found among healthy women who had at least one familial history of ovarian cancer (Cramer et al., 1994b). The Duarte variant has also been correlated with certain histological forms of ovarian cancer (Morland et al., 1998).
Several other authors, however, did not find any correlation between the risk of developing ovarian cancer and dairy food intake, daily galactose consumption, erythrocyte GALT activity, prevalence of low-activity GALT variants or lactase persistence (Risch et al., 1994; Herrinton et al., 1995; Webb et al., 1998; Cozen et al., 2002; Goodman et al., 2002a; Goodman et al., 2002b; Fung et al., 2003; Kuokkanen et al., 2005). In some of these studies, ovarian cancer was associated with a high whole milk and full fat, but not low-fat dairy product, consumption, suggesting that it is the fat component of these products, and not galactose, that possibly increases the cancer risk (Webb et al., 1998). Finally, even the pioneering group of Cramer et al. (2000) agree, in a more recent study, with the preceding results, but they still observe a higher prevalence of low-activity GALT variants in ovarian cancer patients. Recently, most of the abovementioned studies have been included into a large meta-analysis by Qin et al. (2005), who concluded that there is an absence of any significant association between dairy products or galactose metabolism and ovarian cancer.
The male gonad seems to fully escape the toxic effects galactose exerts on the ovary. This has been underlined since the initial descriptions of ovarian failure in galactosaemic patients: in eight male galactosaemics aged between 13 and 28 years, pubertal development occurred normally, and serum gonadotrophin and testosterone levels were in the normal range for all patients (Kaufman et al., 1981). Normal testosterone levels were also detected by other authors in 10 galactosaemic males; however, in the three oldest (21–24 years) of them, elevated serum FSH were measured (Steinman et al., 1981). Nevertheless, there are no published reports on a possible impairment of the reproductive outcome in human galactosaemic males, nor is there any gonadal toxicity in male offspring of galactose-fed rats (Chen et al., 1984).
|
Mechanisms of ovarian damage in galactosaemia |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
A first step in understanding the mechanisms of ovarian damage in galactosaemic patients was the investigation of galactose metabolism in normal ovarian tissue. The ovary contains high enzymatic activities of the three major enzymes of the Leloir pathway. These activities are much higher than in the testis. Moreover, the UDP-galactose and UDP-glucose content of the ovary is significantly higher than that of the testis, suggesting that there is an increased synthesis of glycosylated proteins or lipids in the female gonad when compared with the male (Xu et al., 1989
). As far as GALT is concerned, expression and activity are highest in the liver, followed by the ovary, cerebellum and kidney (Heidenreich et al., 1993). It is these organs that are most likely to be damaged in galactosaemia. Conversely, GALT expression is lowest in testis, which is consistent with the absence of a reproductive phenotype in GALT-deficient males. In general, clinical and biological signs of an enzyme deficiency may result either from the accumulation of the substrates or from a lack of the products of the enzymatic reaction. In galactosaemia, galactose, galactose-1-phosphate and galactitol exhibit intracellular accumulation, whereas a lack in UDP-galactose has been suggested by several authors; however, it still remains controversial.
To investigate the mechanisms underlying the toxic effects of galactose and its metabolites on the human ovary as well as on other organs, two different animal models have been considered.
First, a dietary excess in pregnant rats fed with 50% galactose led to a significant reduction in the number of oocytes in their female offspring, whether the galactose-rich diet was given during embryogenesis only or during the whole gestation (Chen et al., 1981). The same diet given to adult, non-pregnant female mice for 2–6 weeks resulted in a reduction in the number of spontaneous ovulations as well as in a diminished ovarian response to gonadotrophin stimulation. These effects were reversible at the end of the galactose exposure (Swartz and Mattison, 1988). Similar observations were made in 50% of galactose-fed prepubertal rats (Meyer et al., 1992), and, more recently, by an Indian group who fed pregnant rats with a 35% galactose diet from day 3 post-ovulation to the end of gestation (Bandyopadhyay et al., 2003). This study revealed multiple effects of high galactose exposure in utero: when compared with the controls, galactose-exposed litters showed a lower growth rate, a delayed vaginal opening and longer estrous cycle. They also had smaller ovaries with no graafian follicles or corpora lutea and more atretic follicles, lower estradiol and higher FSH serum levels as well as a weaker ovarian response to exogenous gonadotrophin stimulation (Bandyopadhyay et al., 2003). However, another group emphasized the observation that galactose given in the form of lactose seemed to be much less toxic to the ovaries than when animals were fed directly with galactose (Liu et al., 2005).
Second, gene targeting has been used to produce a GALT-deficient mouse lineage, showing biochemical abnormalities similar to the human disease: undetectable GALT activity in homozygous animals, elevated serum galactose levels, high galactose-1-phosphate content in liver and erythrocytes and detectable galactitol (which is undetectable in healthy controls). However, in contrast to the human disease, these mice did not present acute galactose toxicity in the neonate, and females had normal fertility (Leslie et al., 1996).
Thus, neither of these models can be compared directly to the human disease, but both of them provided new insights into galactose metabolism and pathophysiology, as described later.
Accumulation of galactose metabolites
Galactose-1-phosphate has been believed to be the major toxic metabolite of galactose, as there is neither a dramatic neonatal disease nor a poor neurological or ovarian outcome in patients with GALK deficiency, whose galactose-1-phosphate synthesis is blocked, or in most patients with galactose epimerase deficiency, who present only with moderately elevated galactose-1-phosphate levels. The accumulation of this metabolite has been thought to alter the energy production of the cell by inhibiting several enzymes of the glucose metabolism, such as phosphoglucomutase, glucose-6-phosphate dehydrogenase, glycogen phosphorylase and UGP2 (Liu et al., 2000). In vitro, human fibroblasts from galactosaemic patients cease growing when cultured in galactose-containing medium, but this effect can be overcome in the presence of inosine, the ribose moiety of which was supposed to provide an alternative energy source (Pourci et al., 1990). More recently, the impact of galactose-1-phosphate has been investigated at the molecular level in GALT-deficient yeast (Slepak et al., 2005). These micro-organisms also stop growing in vitro when exposed to galactose (Douglas and Hawthorne, 1964). In this model, a galactose challenge did not diminish the production of ATP but induced a series of gene expression modifications, as it was shown using a DNA microarray, especially concerning genes involved in RNA metabolism, ribosomal protein synthesis and inositol turnover. Interestingly, in GALK-deficient yeast cells, which do not produce galactose-1-phosphate, no similar alterations were observed, neither before nor after galactose adjunction, which is consistent with the much less severe phenotype of this deficiency in humans (Slepak et al., 2005).
The role of galactitol in ovarian toxicity has been demonstrated in rats fed with 40% galactose (Meyer et al., 1992). In these animals, an abnormal oocyte maturation and a decreased ovarian response to exogenous gonadotrophin stimulation were observed. The simultaneous administration of an aldose reductase inhibitor, however, prevented all of these abnormalities, suggesting a determining role of galactitol in ovarian galactose toxicity. In fact, it has been known for a long time that in galactose-fed rats, galactitol concentration is elevated in the ovary, even higher than in the liver (Stewart et al., 1968). A further argument underlining the importance of galactitol is based on one of the major differences between human galactosaemia and mouse GALT deficiency. Mice have very low aldose reductase activity, and in the GALT knock out, even if galactitol becomes detectable, its tissue concentration remains low, when compared with the more than 100-fold higher levels found in tissues of galactosaemic patients (Wells et al., 1965; Ning et al., 2000). Therefore, mice may be resistant to galactose-induced tissue damage, because of a reduced galactitol production.
Galactitol does not cross cell membranes easily; therefore, its accumulation within the cells leads to an osmotic imbalance and a water influx, thus altering membrane permeability and cell functions. Moreover, galactitol-induced membrane alterations also account for a loss in cellular glutathione, which leads to an increased sensitivity to oxidative stress (Lou et al., 1988). The latter may also be a major determinant in neurological toxicity, as has been recently suggested in transgenic mice overexpressing aldose reductase specifically in Schwann cells (Song et al., 2003). When fed with a high-galactose diet, or when induced to become diabetic, these animals showed a significant reduction in their motor nerve conduction velocity, which was not correlated with galactitol or sorbitol concentrations but rather with the level of reduced glutathione in the sciatic nerve, indicating that aldose reductase is strongly contributing to the oxidative stress in the nerve.
In human galactosaemia, an excess of galactitol is detected in amniotic fluid of the homozygous fetus; thus its toxic effects may occur even in the embryonic period, which has been confirmed in the rat model (Jakobs et al., 1988; Segal, 1995b). Afterwards, during childhood and adulthood, plasma and urine galactitol levels never return to normal, even in cases of a strict compliance to the galactose-restricted diet. Tissue galactitol concentrations in the human ovary have not been determined, but it has been shown that in human brain, galactitol accumulated only in the fetus and neonate (Irons et al., 1985; Berry et al., 2001a; Wang et al., 2001). In galactosaemic adults, concentrations were not different from those of healthy controls (Moller et al., 1995), suggesting a possible role of this metabolite in acute toxicity, but not in long-term neurological complications. Similarly, elevated galactitol levels alone do not account for the phenotype of ovarian failure seen in galactosaemic patients, as there is no ovarian dysfunction in patients with GALK deficiency who present with high galactitol but normal galactose-1-phosphate levels. This led to the hypothesis that a combination of galactose-1-phosphate and galactitol excess might be necessary to induce ovarian damage (Ning et al., 2000).
Abnormal glycosylation: a UDP-galactose insufficiency?
Another hypothesis as to the pathogenesis of galactosaemia focused on the observation of abnormal glycosylation patterns of several glycoproteins or glycolipids, especially in brain tissue, but also in fibroblasts of galactosaemic patients (Haberland et al., 1971; Petry et al., 1991; Ornstein et al., 1992). Subsequently, these abnormalities have been confirmed in other glycoproteins such as serum transferrin, which normally contains 86% of disialylated biantennary glycans versus only 13% in galactosaemic patients. This abnormal glycosylation pattern significantly improved under a galactose-free diet, but without normalizing completely (Charlwood et al., 1998).
Glycosylation defects have been hypothesized to account for some of the neurological long-term complications of galactosaemia. Indeed, brain tissue of a galactosaemic neonate presented a reduced content of galactose- or N-acetylgalactosamine-containing glycosphingolipids, which are major components of the myelin sheath (Petry et al., 1991). The importance of these biochemical pathways is consistent with a specific GALT expression in the myelin-producing Schwann cells (Daude et al., 1996a). A deficient myelination could therefore underlie the cerebellar symptoms such as ataxia and tremor as well as the cognitive dysfunction, which appears in over 50% of the galactosaemic patients.
Similarly, glycosylation abnormalities could be involved in ovarian dysfunction, e.g. by impairing the interaction between gonadotrophins and their receptors. In fact, the correlation between GALT expression and the synthesis of gonadotrophins in the anterior pituitary gland in the rat is consistent with a possible role of GALT and its reaction products in this synthesis (Daude et al., 1996b). Subsequently, an abnormal glycosylation pattern of FSH has been demonstrated in three of four female galactosaemic patients, with a partial absence of terminal disaccharides containing galactose and sialic acid, leading to a neutral isoform, which coexisted with normal, acid isoforms (Prestoz et al., 1997). Deglycosylated isoforms of FSH are able to bind to their transmembrane receptor but not to activate the signal transduction system (Sairam, 1989). Particularly, disialylated recombinant human FSH showed very reduced in vivo bioactivity as well as a shortened half-life in immature rats, when compared with wild-type FSH (Galway et al., 1990). Similarly, the hypothesis of some defective endogenous gonadotrophins has been raised to explain different patterns of ovarian response to exogenous gonadotrophin stimulation in galactose-fed rats (Bandyopadhyay et al., 2003). The percentage of ovulation and the number of retrieved oocytes were significantly higher after pituitary desensitization with a GnRH agonist than in animals without this down-regulation, thus suggesting an interference by potentially inactive or even antagonistic endogenous FSH isoforms which would have been suppressed by agonist pretreatment. A further group suggested an acquired anomaly of the gonadotrophin receptor (Fraser et al., 1986), leading to a gonadotrophin-resistant ovary syndrome, as this was also observed in galactose-fed mice (Swartz and Mattison, 1988) and rats (Bandyopadhyay et al., 2003).
However, other authors did not find any reduction in the uterine weight of mice injected with FSH from 24-h urine collections of galactosaemic patients compared with urinary FSH from healthy controls (Kaufman et al., 1981). These authors highlighted the fact that some galactosaemic patients had a successful pregnancy before the onset of POF and that gonadotrophins function normally in males; thus their observations were not consistent with the hypothesis of an abnormally glycosylated FSH as the only pathogenic mechanism in galactosaemia.
While there is a growing body of evidence for glycosylation defects in galactosaemia, the mechanisms leading to these abnormalities are still a matter of debate. First, it has been suggested that GALT deficiency induced a lack of UDP-galactose, as this is one of the GALT reaction products, and also the indispensable substrate for subsequent galactosylation. Initially, low levels of UDP-galactose were measured by biochemical methods in liver biopsy samples, cultured fibroblasts and erythrocytes from galactosaemic patients compared with healthy control subjects (Ng et al., 1989). However, with the use of more accurate methods, such as high-performance liquid chromatography (HPLC), only the difference in erythrocyte UDP-galactose was confirmed, although there was a large overlap between cases and controls (Berry et al., 1992; Keevill et al., 1993). In contrast, UDP-galactose content in leukocytes and fibroblasts did not appear to be diminished in galactosaemic patients (Gibson et al., 1994; Keevill et al., 1994). This discrepancy was explained by the inability of red blood cell UDP-galactose epimerase to maintain a normal level of UDP-galactose in these cells (Segal, 1995a). As to UDP-galactose levels in other tissues, there is only very scarce information; recently, the drop of brain tissue UDP-galactose levels below a certain threshold value has been hypothesized to impair the function of cerebroside galactosyltransferase and thus the synthesis of galactosphingolipids (Lebea and Pretorius, 2005), but no measures were underlying this hypothesis.
Second, as there is no clear evidence for an insufficient UDP-galactose availability, abnormal galactosylation may also be the consequence of an inhibition of galactosyltransferase reactions by galactose or one of its accumulating metabolites. Galactose-1-phosphate has been shown to moderately inhibit galactosyltransferases at high concentrations (81% of control activity at 125 µM) in chick embryo neural retina cells (Roth et al., 1971). In contrast, other authors described an increased activity of galactosyltransferases in cultured fibroblast extracts from galactosaemic patients, suggesting a compensatory mechanism in these cells (Ornstein et al., 1992).
Third, galactose and its derivatives may interfere with other enzymes involved in the synthesis of UDP-galactose or its transport into the mitochondria. Recently, a competitive inhibition of UGP2 by galactose-1-phosphate has been investigated in immortalized human fibroblasts derived from a galactosaemic patient (Lai et al., 2003a). These cells showed a lower UDP-galactose and UDP-glucose content than a control cell line with normal GALT activity. They also accumulated galactose-1-phosphate and stopped growing when transferred to a galactose-containing medium. Upon transfection with either human GALT or UGP2 gene, UDP-hexoses increased to normal values, and there was no more galactose-1-phosphate accumulation; moreover, transfected cells resumed growing in the presence of galactose. Thus, replacing the lacking enzyme as well as overexpressing UGP2 allowed the rescue of these GALT-deficient cells. It was therefore hypothesized that the beneficial effect of UGP2 transfection resulted from an increased conversion of toxic galactose-1-phosphate into UDP-galactose and from a re-equilibration of intracellular UDP-sugar levels. Consistently, the authors also showed galactose-1-phosphate to competitively inhibit UGP2 as well as another UDP-sugar pyrophosphorylase (UDP-N-acetylglucosamine pyrophosphorylase).
Taken together, these results led to the conclusion that glycosylation defects in galactosaemia result from both the absence of GALT and the accumulation of toxic galactose derivatives.
Activation of follicular apoptosis
Apoptosis or programmed cell death has already been described in inborn errors of metabolism (Monici et al., 1998; Jouvet et al., 2000; Mirabella et al., 2000) and is an essential phenomenon in ovarian physiology, occurring at all periods of life; from the colonization of the genital crest by the primordial germ cells up to the cessation of ovarian activity at menopause, ovarian germ cells and follicle somatic cells are eliminated by activation of apoptotic processes (Rolaki et al., 2005). Indeed, apoptotic death, also called atresia, is the normal fate of over 99.9% of ovarian follicles, whereas only a very few of them will be allowed to complete folliculogenesis up to ovulation and corpus luteum formation (Vaskivuo and Tapanainen, 2003). Generally, apoptosis can be activated either by endogenous, intracellular mechanisms, resulting from an imbalance between pro-apoptotic and anti-apoptotic factors, or by exogenous, extracellular mechanisms, after binding of pro-apoptotic factors to specific membrane receptors. Most of the morphological and functional alterations seen in apoptotic cells can be accounted for by a family of enzymes, the caspases, which become activated in a reaction cascade. The current knowledge on apoptotic mechanisms in ovarian physiology has been recently reviewed elsewhere (Pru and Tilly, 2001; Hussein, 2005).
The possible involvement of apoptotic mechanisms in galactose-induced tissue damage has been evidenced first in ophthalmologic complications of galactosaemia. It has been known for a long time that in several animal models a galactose-enriched diet induced cataract and retinal damage similar to what can be seen in diabetes mellitus.
Cataract formation in hypergalactosaemic or diabetic animals is caused by accumulation of polyols in lens epithelial cells which present with multiple vacuoles within their cytoplasm. Recently, it has been reported that dog lens epithelial cells show DNA fragmentation when cultured in the presence of high galactose concentrations (Murata et al., 2001). The authors also showed that activation of apoptosis preceded the appearance of cytoplasmic vacuoles and that these alterations could be prevented by the adjunction of an aldose reductase inhibitor to the culture medium. Thus, galactitol seems to be a major determinant in the activation of apoptosis in the lens, as has been reported earlier in hypergalactosaemic retinopathy (Sato et al., 1999). In that study, apoptosis in retinal capillary pericytes could also be prevented by the same aldose reductase inhibitor.
Little is known, however, about the mechanisms that lead to the activation of apoptosis in these models. In a recent hypergalactosaemic mouse model, retinal cell extracts were analysed after different periods of galactose exposure: caspases 1, 4 and 5 became activated after 2 months of exposure, followed by caspase 6 after 6 months and caspase 9 after 9 months (Mohr et al., 2002). The caspase activation sequence was different in diabetic mice, suggesting different apoptosis-activating mechanisms in these two disease models.
The possibility of a similar apoptotic damage in the galactosaemic ovary has been recently investigated in rats (Lai et al., 2003b). These authors fed immature rats with a 50% galactose diet for 2–8 weeks and afterwards stimulated their ovaries with exogenous gonadotrophins. They first confirmed high erythrocyte galactose-1-phosphate, cataract formation, growth retardation and a lower number oocytes and corpora lutea after stimulation, as reported earlier. Interestingly, western blot analysis of ovarian extracts revealed a higher Fas and Fas-ligand as well as a lower Riap (rat inhibitor of apoptosis proteins) and Xiap (X-linked inhibitor of apoptosis proteins) content in hypergalactosaemic rats when compared with controls. Fas is a transmembrane receptor that initiates apoptosis after binding of its ligand, whereas Riap and Xiap are part of the anti-apoptotic regulators. Thus, galactose exposure favours the activation of apoptosis in the rat ovary.
Among intraovarian factors regulating folliculogenesis, GDF-9 has been extensively investigated (Aaltonen et al., 1999; Lin et al., 2003; Juengel and McNatty, 2005). In the human ovary, this member of the transforming growth factor-ß superfamily is expressed mainly in oocytes but also in the granulosa cells (Sidis et al., 1998). GDF-9 seems to be essential for normal folliculogenesis, as it has been shown to enhance follicle growth and development up to the secondary stage (Hreinsson et al., 2002b) as well as shown to promote granulosa and theca cell differentiation in early antral and preovulatory follicles (Vitt and Hsueh, 2001). As there is a reduction in the number of growing follicles in galactose-fed rats, GDF-9 was a potential target of galactose toxicity in the ovary. Liu et al. (2006) showed that female rats fed with a 20% galactose diet between day 21 and day 40, i.e. before the first ovulation, present with a significant reduction in the number of growing follicles, whereas the number of primordial and atretic follicles was not changed, when compared with control animals. Moreover, western blot analysis of whole ovarian extracts in hypergalactosaemic animals revealed a strong decline in GDF-9 levels, principally in propeptide but also in mature isoforms. The authors therefore suggested that the decrease in oocyte GDF-9 expression accounted for the diminished number of growing follicles and thus represented an important mechanism of galactose toxicity. However, a possible effect on the mRNA level has not been investigated in that study, and it is not clear whether the observed reduction of GDF-9 content in whole ovarian extracts was the cause or the consequence of the decreased number of growing follicles.
|
Clinical management of ovarian toxicity in galactosaemic patients |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
Pharmacological prevention
Several preventive strategies have been put forward to avoid or reduce long-term complications in galactosaemia. Antioxidants have been shown to delay the development of galactitol-induced cataract (Yokoyama et al., 1994; Ohta et al., 1997) and retinopathy (Kowluru et al., 2001) in animal models.
Based on the hypothesis of an insufficient UDP-galactose availability in galactosaemic patients and the observation of a significant increase of erythrocyte UDP-galactose levels in vitro, after uridine adjunction to the culture medium, uridine administration has been proposed as a treatment (Ng et al., 1989). However, the only published therapeutic trial using uridine supplementation in 29 patients over 2–5 years did not show any benefit when compared with galactose-restricted diet alone, as far as neurocognitive performance was concerned (Manis et al., 1997).
The abovementioned role of aldose reductase in the pathophysiology of galactosaemia as well as the preventive effect of aldose reductase inhibitors on galactose-induced ovarian toxicity in rats (Meyer et al., 1992) and ocular damage in dogs (Murata et al., 2001; Murata et al., 2002) suggest that these drugs could also improve clinical outcome in human galactosaemics. However, clinical trials with aldose reductase inhibitors have been used so far only in diabetic patients (Oka and Kato, 2001).
Efforts have to be made to produce enzyme activators which could stimulate residual GALT activity or enhance alternative pathways, such as galactonate formation, to accelerate galactose oxidation, until, sometime in the future, enzyme replacement (Brady, 2006) or gene therapy will become available for these patients.
Assuming that ovarian toxicity is not restricted exclusively to the prenatal life but progressing throughout childhood and adolescence, it is important to inform young galactosaemic girls who present with a spontaneous puberty about the risk of developing ovarian failure and to counsel them for not unnecessarily postponing pregnancy. In the absence of a male partner, oocyte cryopreservation after ovarian stimulation might also be discussed. Despite the low number of children born after IVF of frozen–thawed oocytes during the last 25 years, several recent improvements of mature oocyte freezing and thawing procedures (Fabbri et al., 2001; Porcu, 2001; Van der Elst, 2003) have made this technique a real alternative for preserving fertility in young galactosaemic patients. It has also been suggested to protect the follicular reserve from galactose-induced damage by ovarian tissue cryopreservation and subsequent autografting of the preserved tissue. This rapidly developing but still experimental technology is currently proposed in young females undergoing chemotherapy or pelvic irradiation and thus at risk for iatrogenic ovarian failure and premature menopause. The standard procedure of ovarian tissue cryopreservation comprises laparoscopic retrieval of one ovary (or part of an ovary) followed by dissection of the ovarian cortex into small slices, which will be incubated with a cryoprotectant solution and then cooled according to a similar protocol as for oocytes or embryos. Alternatively, as for oocytes, vitrification of the ovarian tissue may be performed, and there are also some promising experiments with whole ovary freezing. These techniques have been recently reviewed elsewhere (Hovatta, 2005; Kim, 2006). Although there have not yet been many transplantations carried out until now, two healthy babies have been born after autografting of previously cryopreserved ovarian tissue in two patients who had been cured of malignant lymphoma (Donnez et al., 2004; Meirow et al., 2005). However, as for Turner’s syndrome, where a progressive follicular loss is occurring (Abir et al., 2001; Hreinsson et al., 2002a), there are currently no reliable clinical or biological criteria to select those galactosaemic patients who could benefit from ovarian tissue banking, nor is it known at which time ovarian tissue retrieval would have to be performed: should ovarian tissue cryopreservation be performed during the first years of life, in prepubertal girls, or only after a spontaneous puberty, indicating persistence of ovarian function? Moreover, there are also ethical concerns with harvesting ovarian tissue or with stimulating ovarian function in minor patients.
HRT in galactosaemic females is aimed to induce pubertal development in girls with early ovarian failure and hypogonadism, to treat clinical hypoestrogenism and to prevent long-term complications of hypoestrogenism, particularly bone density loss. The United Kingdom Galactosaemia Steering Group recommends referral to a paediatric endocrinologist from the age of 10, and hormonal treatment from 12 to 13 years, starting with ethinyl estradiol (EE), 2 µg daily for the first year, 5 µg daily for the second and 10 µg daily for the third year. Afterwards, combined oral contraception containing 20 µg of EE and a progestin will be suitable (Walter et al., 1999). In patients who do not wish any contraceptive effect, artificial cycles with sequential administration of natural estradiol and micronized progesterone can be used. Most of the reported spontaneous pregnancies in patients with incipient POF occur under this type of treatment. In some cases, high-dose administration of exogenous gonadotrophins may also be successful (Check et al., 1990). The earlier-mentioned pregnancies in patients with galactosaemia all occurred spontaneously, in the absence of any specific treatment. In one case report, however, the authors reported a successful pregnancy in a 26-year-old galactosaemic patient who presented with ovarian failure since the age of 19 (Menezo et al., 2004). In this patient, after an artificial cycle to decrease circulating gonadotrophin levels, exogenous recombinant FSH stimulation led to the development of a dominant follicle and spontaneous pregnancy. Thus, as in other POF aetiologies, there is no standardized procedure to treat infertility in these patients, and after several therapies without success, patients should be counselled to accept either oocyte donation or adoption.
|
Conclusions |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
Excessive amounts of galactose in blood and tissues lead to acute and chronic toxicity, as it is described in inborn errors of galactose metabolism such as GALT deficiency, also called classical galactosaemia. In this enigmatic condition, although acute toxicity will completely regress with the onset of a galactose-restricted diet, long-term complications including cognitive and motor abnormalities as well as ovarian failure remain unavoidable. The pathogenesis of galactose-induced ovarian toxicity is still unclear but probably involves galactose itself and its metabolites, such as galactitol, galactonate and UDP-galactose. Several mechanisms of ovarian damage have been hypothesized, such as direct toxicity of galactose and metabolites, oxidative stress and activation of apoptosis. A better characterization of patients as to their genotype, galactose oxidation capacities and involvement of alternative biochemical pathways will be needed to progress in our comprehension of this disease. In the absence of any aetiological treatment of ovarian failure in galactosaemics, emphasis has to be made on future preventive strategies as well as on the need for hormonal replacement in these estrogen-deprived patients.
|
References |
|---|
|
TOPAbstractGalactose: origins and...Pathology of galactose...Ovarian dysfunction in classical...Mechanisms of ovarian damage...Clinical management of ovarian...ConclusionsReferences |
|---|
Aaltonen J, Laitinen MP, Vuojolainen K, Jaatinen R, Horelli-Kuitunen N, Seppa L, Louhio H, Tuuri T, Sjoberg J, Butzow R et al. (1999) Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9B are expressed in oocytes during early folliculogenesis. J Clin Endocrinol Metab 84,2744–2750.
Abir R, Fisch B, Nahum R, Orvieto R, Nitke S and Ben Rafael Z (2001) Turner’s syndrome and fertility: current status and possible putative prospects. Hum Reprod Update 7,603–610.
Acosta PB and Gross KC (1995) Hidden sources of galactose in the environment. Eur J Pediatr 154,S87–S92.[CrossRef][Web of Science][Medline]
Bandyopadhyay S, Chakrabarti J, Banerjee S, Pal AK, Goswami SK, Chakravarty BN and Kabir SN (2003) Galactose toxicity in the rat as a model for premature ovarian failure: an experimental approach readdressed. Hum Reprod 18,2031–2038.
Berry GT, Palmieri MJ, Heales S, Leonard JV and Segal S (1992) Red blood cell uridine sugar nucleotide levels in patients with classic galactosemia and other metabolic disorders. Metabolism 41,783–787.[CrossRef][Web of Science][Medline]
Berry GT, Hunter JV, Wang Z, Dreha S, Mazur A, Brooks DG, Ning C, Zimmerman RA and Segal S (2001a) In vivo evidence of brain galactitol accumulation in an infant with galactosemia and encephalopathy. J Pediatr 138,260–262.[CrossRef][Web of Science][Medline]
Berry GT, Leslie N, Reynolds R, Yager CT and Segal S (2001b) Evidence for alternate galactose oxidation in a patient with deletion of the galactose-1-phosphate uridyltransferase gene. Mol Genet Metab 72,316–321.[CrossRef][Web of Science][Medline]
Bosch AM, Bakker HD, van Gennip AH, van Kempen JV, Wanders RJ and Wijburg FA (2002) Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis 25,629–634.[CrossRef][Web of Science][Medline]
Berry GT, Moate PJ, Reynolds RA, Yager CT, Ning C, Boston RC and Segal S (2004a) The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab 81,22–30.[CrossRef][Web of Science][Medline]
Berry GT, Reynolds RA, Yager CT and Segal S (2004b) Extended [13C]galactose oxidation studies in patients with galactosemia. Mol Genet Metab 82,130–136.[CrossRef][Web of Science][Medline]
Bosch AM, Ijlst L, Oostheim W, Mulders J, Bakker HD, Wijburg FA, Wanders RJ and Waterham HR (2005) Identification of novel mutations in classical galactosemia. Hum Mutat 25,502.
Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57,283–296.[CrossRef][Web of Science][Medline]
Briones P, Giros M and Martinez V (2001) Second spontaneous pregnancy in a galactosaemic woman homozygous for the Q188R mutation. J Inherit Metab Dis 24,79–80.[CrossRef][Web of Science][Medline]
Charlwood J, Clayton P, Keir G, Mian N and Winchester B (1998) Defective galactosylation of serum transferrin in galactosemia. Glycobiology 8, 351–357.
Check JH, Nowroozi K, Chase JS, Nazari A, Shapse D and Vaze M (1990) Ovulation induction and pregnancies in 100 consecutive women with hypergonadotropic amenorrhea. Fertil Steril 53,811–816.[Web of Science][Medline]
Chen YT, Mattison DR, Feigenbaum L, Fukui H and Schulman JD (1981) Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science 214,1145–1147.
Chen YT, Mattison DR, Bercu BB and Schulman JD (1984) Resistance of the male gonad to a high galactose diet. Pediatr Res 18,345–348.[Web of Science][Medline]
Cooper GS, Hulka BS, Baird DD, Savitz DA, Hughes CL Jr, Weinberg CR, Coleman RA and Shields JM (1994) Galactose consumption, metabolism, and follicle-stimulating hormone concentrations in women of late reproductive age. Fertil Steril 62,1168–1175.[Web of Science][Medline]
Cozen W, Peters R, Reichardt JK, Ng W, Felix JC, Wan P and Pike MC (2002) Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control 13,113–120.[CrossRef][Web of Science][Medline]
Cramer DW (1989) Lactase persistence and milk consumption as determinants of ovarian cancer risk. Am J Epidemiol 130,904–910.
Cramer DW, Harlow BL, Barbieri RL and Ng WG (1989a) Galactose-1-phosphate uridyl transferase activity associated with age at menopause and reproductive history. Fertil Steril 51,609–615.[Web of Science][Medline]
Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG and Knapp RC (1989b) Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 2,66–71.[CrossRef][Web of Science][Medline]
Cramer DW, Barbieri RL, Xu H and Reichardt JK (1994a) Determinants of basal follicle-stimulating hormone levels in premenopausal women. J Clin Endocrinol Metab 79,1105–1109.[Abstract]
Cramer DW, Muto MG, Reichardt JK, Xu H, Welch WR, Valles B and Ng WG (1994b) Characteristics of women with a family history of ovarian cancer. I. Galactose consumption and metabolism. Cancer 74,1309–1317.[CrossRef][Web of Science][Medline]
Cramer DW, Xu H and Sahi T (1994c) Adult hypolactasia, milk consumption, and age-specific fertility. Am J Epidemiol 139,282–289.
Cramer DW, Greenberg ER, Titus-Ernstoff L, Liberman RF, Welch WR, Li E and Ng WG (2000) A case-control study of galactose consumption and metabolism in relation to ovarian cancer. Cancer Epidemiol Biomarkers Prev 9,95–101.
Daude N, Ellie E, Reichardt JK and Petry KG (1996a) In vivo and in vitro expression of rat galactose-1-phosphate uridyltransferase (GALT) in the developing central and peripheral nervous system. Brain Res Dev Brain Res 94,190–196.[Medline]
Daude N, Lestage J, Reichardt JK and Petry KG (1996b) Expression of galactose-1-phosphate uridyltransferase in the anterior pituitary of rat during the estrous cycle. Neuroendocrinology 64,42–48.[Web of Science][Medline]
de Jongh S, Vreken PLIJ, Wanders RJ, Jakobs C and Bakker HD (1999) Spontaneous pregnancy in a patient with classical galactosaemia. J Inherit Metab Dis 22,754–755.[CrossRef][Web of Science][Medline]
Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B and van Langendonckt A (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364,1405–1410.[CrossRef][Web of Science][Medline]
Douglas HC and Hawthorne DC (1964) Enzymatic expression and genetic linkage of genes controlling galactose utilization in saccharomyces. Genetics 49,837–844.
Elsas LJ, Lai K, Saunders CJ and Langley SD (2001) Functional analysis of the human galactose-1-phosphate uridyltransferase promoter in Duarte and LA variant galactosemia. Mol Genet Metab 72,297–305.[CrossRef][Web of Science][Medline]
Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S and Flamigni C (2001) Human oocyte cryopreservation: new perspectives regarding oocyte survival. Hum Reprod 16,411–416.
Fraser IS, Russell P, Greco S and Robertson DM (1986) Resistant ovary syndrome and premature ovarian failure in young women with galactosaemia. Clin Reprod Fertil 4,133–138.[Medline]
Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D and Narod SA (2003) The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 12,678–680.
Galway AB, Hsueh AJ, Keene JL, Yamoto M, Fauser BC and Boime I (1990) In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology 127,93–100.
Gibson JB, Reynolds RA, Palmieri MJ, States B, Berry GT and Segal S (1994) Uridine diphosphate hexoses in leukocytes and fibroblasts of classic galactosemics and patients with other metabolic diseases. Pediatr Res 36,613–618.[Web of Science][Medline]
Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt JK and Ng WG (2002a) Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer. Am J Epidemiol 156,693–701.
Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, Terada K, Wilkens LR, Murphy S and Hankin JH (2002b) Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol 156,148–157.
Guerrero NV, Singh RH, Manatunga A, Berry GT, Steiner RD and Elsas LJ II (2000) Risk factors for premature ovarian failure in females with galactosemia. J Pediatr 137,833–841.[CrossRef][Web of Science][Medline]
Haberland C, Perou M, Brunngraber EG and Hof H (1971) The neuropathology of galactosemia. A histopathological and biochemical study. J Neuropathol Exp Neurol 30,431–447.[Web of Science][Medline]
Hagenfeldt K, von Dobeln U and Hagenfeldt L (1989) Gonadal failure in young women and galactose-1-phosphate uridyl transferase activity. Fertil Steril 51,177–178.[Web of Science][Medline]
Heidenreich RA, Mallee J, Rogers S and Segal S (1993) Developmental and tissue-specific modulation of rat galactose-1-phosphate uridyltransferase steady state messenger RNA and specific activity levels. Pediatr Res 34,416–419.[Web of Science][Medline]
Herrinton LJ, Weiss NS, Beresford SA, Stanford JL, Wolfla DM, Feng Z and Scott CR (1995) Lactose and galactose intake and metabolism in relation to the risk of epithelial ovarian cancer. Am J Epidemiol 141,407–416.
Herrinton LJ, Lemaitre RN, Beresford SA, Stanford JL, Wolfla DM, Feng Z, Scott CR and Weiss NS (1996) Lactose metabolism and time to pregnancy. Fertil Steril 66,384–388.[Web of Science][Medline]
Hovatta O (2005) Methods for cryopreservation of human ovarian tissue. Reprod Biomed Online 10,729–734.[Web of Science][Medline]
Hreinsson JG, Otala M, Fridstrom M, Borgstrom B, Rasmussen C, Lundqvist M, Tuuri T, Simberg N, Mikkola M, Dunkel L et al. (2002a) Follicles are found in the ovaries of adolescent girls with Turner’s syndrome. J Clin Endocrinol Metab 87,3618–3623.
Hreinsson JG, Scott JE, Rasmussen C, Swahn ML, Hsueh AJ and Hovatta O (2002b) Growth differentiation factor-9 promotes the growth, development, and survival of human ovarian follicles in organ culture. J Clin Endocrinol Metab 87,316–321.
Hussein MR (2005) Apoptosis in the ovary: molecular mechanisms. Hum Reprod Update 11,162–177.
Irons M, Levy HL, Pueschel S and Castree K (1985) Accumulation of galactose-1-phosphate in the galactosemic fetus despite maternal milk avoidance. J Pediatr 107,261–263.[CrossRef][Web of Science][Medline]
Jakobs C, Kleijer WJ, Bakker HD, van Gennip AH, Przyrembel H and Niermeijer MF (1988) Dietary restriction of maternal lactose intake does not prevent accumulation of galactitol in the amniotic fluid of fetuses affected with galactosaemia. Prenat Diagn 8,641–645.[Web of Science][Medline]
Jouvet P, Kozma M and Mehmet H (2000) Primary human fibroblasts from a maple syrup urine disease patient undergo apoptosis following exposure to physiological concentrations of branched chain amino acids. Ann N Y Acad Sci 926,116–121.[Web of Science][Medline]
Juengel JL and McNatty KP (2005) The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development. Hum Reprod Update 11,143–160.[Medline]
Kaufman F, Kogut MD, Donnell GN, Koch H and Goebelsmann U (1979) Ovarian failure in galactosaemia. Lancet 2,737–738.[CrossRef][Web of Science][Medline]
Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C and Koch R (1981) Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 304,994–998.[Abstract]
Kaufman FR, Xu YK, Ng WG and Donnell GN (1988) Correlation of ovarian function with galactose-1-phosphate uridyl transferase levels in galactosemia. J Pediatr 112,754–756.[CrossRef][Web of Science][Medline]
Kaufman FR, Xu YK, Ng WG, Silva PD, Lobo RA and Donnell GN (1989) Gonadal function and ovarian galactose metabolism in classic galactosemia. Acta Endocrinol (Copenh) 120,129–133.
Kaufman FR, Devgan S and Donnell GN (1993) Results of a survey of carrier women for the galactosemia gene. Fertil Steril 60,727–728.[Web of Science][Medline]
Kaufman FR, Reichardt JK, Ng WG, Xu YK, Manis FR, McBride-Chang C and Wolff JA (1994) Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene. J Pediatr 125,225–227.[CrossRef][Web of Science][Medline]
Keevill NJ, Holton JB and Allen JT (1993) The investigation of UDPGlucose and UDPGalactose concentration in red blood cells of patients with classical galactosaemia. Clin Chim Acta 221,135–142.[Medline]
Keevill NJ, Holton JB and Allen JT (1994) UDP-glucose and UDP-galactose concentrations in cultured skin fibroblasts of patients with classical galactosaemia. J Inherit Metab Dis 17,23–26.[CrossRef][Web of Science][Medline]
Kim SS (2006) Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 85,1–11.[CrossRef][Web of Science][Medline]
Kimonis V (2001) Increased fertility in a woman with classic galactosaemia. J Inherit Metab Dis 24,607–608.[Web of Science][Medline]
Kowluru RA, Tang J and Kern TS (2001) Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50, 1938–1942.
Kumar KA, Rao KL, Vedula SV, Kanakavalli MK, Vaddamani PV, Deendayal M, Gupta N, Chakravarthy BN and Singh L (2005) Screening of the galactose-1-phosphate uridyltransferase gene in Indian women with ovarian failure. Reprod Biomed Online 11,444–448.[Web of Science][Medline]
Kuokkanen M, Butzow R, Rasinpera H, Medrek K, Nilbert M, Malander S, Lubinski J and Jarvela I (2005) Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden. Int J Cancer 117,90–94.[CrossRef][Web of Science][Medline]
Lai K and Elsas LJ (2000) Overexpression of human UDP-glucose pyrophosphorylase rescues galactose-1-phosphate uridyltransferase-deficient yeast. Biochem Biophys Res Commun 271,392–400.[CrossRef][Web of Science][Medline]
Lai K, Langley SD, Singh RH, Dembure PP, Hjelm LN and Elsas LJ II (1996) A prevalent mutation for galactosemia among black Americans. J Pediatr 128,89–95.[CrossRef][Web of Science][Medline]
Lai K, Langley SD, Khwaja FW, Schmitt EW and Elsas LJ (2003a) GALT deficiency causes UDP-hexose deficit in human galactosemic cells. Glycobiology 13,285–294.
Lai KW, Cheng LY, Cheung AL and OWS (2003b) Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats. Cell Tissue Res 311,417–425.[Web of Science][Medline]
Landt M, Ritter D, Lai K, Benke PJ, Elsas LJ and Steiner RD (1997) Black children deficient in galactose 1-phosphate uridyltransferase: correlation of activity and immunoreactive protein in erythrocytes and leukocytes. J Pediatr 130,972–980.[CrossRef][Web of Science][Medline]
Langley SD, Lai K, Dembure PP, Hjelm LN and Elsas LJ (1997) Molecular basis for Duarte and Los Angeles variant galactosemia. Am J Hum Genet 60,366–372.[Web of Science][Medline]
Lebea PJ and Pretorius PJ (2005) The molecular relationship between deficient UDP-galactose uridyl transferase (GALT) and ceramide galactosyltransferase (CGT) enzyme function: a possible cause for poor long-term prognosis in classic galactosemia. Med Hypotheses 65,1051–1057.[CrossRef][Web of Science][Medline]
Leslie ND (2003) Insights into the pathogenesis of galactosemia. Annu Rev Nutr 23,59–80.[CrossRef][Web of Science][Medline]
Leslie ND, Immerman EB, Flach JE, Florez M, Fridovich-Keil JL and Elsas LJ (1992) The human galactose-1-phosphate uridyltransferase gene. Genomics 14,474–480.[CrossRef][Web of Science][Medline]
Leslie ND, Yager KL, McNamara PD and Segal S (1996) A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem Mol Med 59,7–12.[CrossRef][Web of Science][Medline]
Levy HL, Driscoll SG, Porensky RS and Wender DF (1984) Ovarian failure in galactosemia. N Engl J Med 310,50.[Web of Science][Medline]
Lin SY, Morrison JR, Phillips DJ and de Kretser DM (2003) Regulation of ovarian function by the TGF-beta superfamily and follistatin. Reproduction 126,133–148.[Abstract]
Liu G, Hale GE and Hughes CL (2000) Galactose metabolism and ovarian toxicity. Reprod Toxicol 14,377–384.[CrossRef][Web of Science][Medline]
Liu G, Shi F, Blas-Machado U, Duong Q, Davis VL, Foster WG and Hughes CL (2005) Ovarian effects of a high lactose diet in the female rat. Reprod Nutr Dev 45,185–192.[CrossRef][Web of Science][Medline]
Liu G, Shi F, Blas-Machado U, Yu R, Davis VL, Foster WG, Magoffin DA and Hughes CL (2006) Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary. Reprod Toxicol 21,26–33.[CrossRef][Web of Science][Medline]
Lou MF, Dickerson JE Jr, Garadi R and York BM Jr (1988) Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res 46,517–530.[Web of Science][Medline]
Lukac Bajalo J, Mencej S, Karas N, Mlinar B, Zitnik IP and Gersak K (2005) Q188R, K285N, and N314D mutation-associated alleles in the galactose-1-phosphate uridyltransferase gene and female infertility. Fertil Steril 83,776–778.[CrossRef][Web of Science][Medline]
Manis FR, Cohn LB, McBride-Chang C, Wolff JA and Kaufman FR (1997) A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine. J Inherit Metab Dis 20,549–555.[CrossRef][Web of Science][Medline]
Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, Schiff E and Dor J (2005) Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 353,318–321.
Meloni GF, Colombo C, La Vecchia C, Ruggiu G, Mannazzu MC, Ambrosini G and Cherchi PL (1999) Lactose absorption in patients with ovarian cancer. Am J Epidemiol 150,183–186.
Menezo YJ, Lescaille M, Nicollet B and Servy EJ (2004) Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report. J Assist Reprod Genet 21,89–90.[CrossRef][Web of Science][Medline]
Meyer WR, Doyle MB, Grifo JA, Lipetz KJ, Oates PJ, DeCherney AH and Diamond MP (1992) Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat. Am J Obstet Gynecol 167,1837–1843.[Web of Science][Medline]
Mirabella M, Di Giovanni S, Silvestri G, Tonali P and Servidei S (2000) Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 123,93–104.
Mlinar B, Gersak K, Karas N, Zitnik IP, Battelino T and Lukac-Bajalo J (2005) Galactose-1-phosphate uridyl transferase gene mutations in women with premature ovarian failure. Fertil Steril 84,253–255.[CrossRef][Web of Science][Medline]
Mohr S, Xi X, Tang J and Kern TS (2002) Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51, 1172–1179.
Moller HE, Ullrich K, Vermathen P, Schuierer G and Koch HG (1995) In vivo study of brain metabolism in galactosemia by 1H and 31P magnetic resonance spectroscopy. Eur J Pediatr 154,S8–S13.[CrossRef][Web of Science][Medline]
Monici MC, Toscano A, Girlanda P, Aguennouz M, Musumeci O and Vita G (1998) Apoptosis in metabolic myopathies. Neuroreport 9,2431–2435.[Web of Science][Medline]
Morland SJ, Jiang X, Hitchcock A, Thomas EJ and Campbell IG (1998) Mutation of galactose-1-phosphate uridyl transferase and its association with ovarian cancer and endometriosis. Int J Cancer 77,825–827.[CrossRef][Web of Science][Medline]
Murata M, Ohta N, Sakurai S, Alam S, Tsai J, Kador PF and Sato S (2001) The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem Biol Interact 130–132,617–625.[Medline]
Murata M, Ohta N, Fujisawa S, Tsai JY, Sato S, Akagi Y, Takahashi Y, Neuenschwander H and Kador PF (2002) Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. J Diabetes Complications 16,363–370.[CrossRef][Web of Science][Medline]
Ng WG, Xu YK, Kaufman FR and Donnell GN (1989) Deficit of uridine diphosphate galactose in galactosaemia. J Inherit Metab Dis 12,257–266.[CrossRef][Web of Science][Medline]
Ning C, Reynolds R, Chen J, Yager C, Berry GT, McNamara PD, Leslie N and Segal S (2000) Galactose metabolism by the mouse with galactose-1-phosphate uridyltransferase deficiency. Pediatr Res 48,211–217.[Web of Science][Medline]
Novelli G and Reichardt JK (2000) Molecular basis of disorders of human galactose metabolism: past, present, and future. Mol Genet Metab 71,62–65.[CrossRef][Web of Science][Medline]
Ohta Y, Torii H, Yamasaki T, Niwa T, Majima Y and Ishiguro I (1997) Preventive action of vitamin E-containing liposomes on cataractogenesis in young adult rats fed a 25% galactose diet. J Ocul Pharmacol Ther 13, 537–550.[Web of Science][Medline]
Oka M and Kato N (2001) Aldose reductase inhibitors. J Enzyme Inhib 16, 465–473.[CrossRef][Web of Science][Medline]
Openo KK, Schulz JM, Vargas CA, Orton CS, Epstein MP, Schnur RE, Scaglia F, Berry GT, Gottesman GS, Ficicioglu C et al. (2006) Epimerase-deficiency galactosemia is not a binary condition. Am J Hum Genet 78,89–102.[CrossRef][Web of Science][Medline]
Ornstein KS, McGuire EJ, Berry GT, Roth S and Segal S (1992) Abnormal galactosylation of complex carbohydrates in cultured fibroblasts from patients with galactose-1-phosphate uridyltransferase deficiency. Pediatr Res 31,508–511.[Web of Science][Medline]
Petry K, Greinix HT, Nudelman E, Eisen H, Hakomori S, Levy HL and Reichardt JK (1991) Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochem Med Metab Biol 46,93–104.[CrossRef][Web of Science][Medline]
Porcu E (2001) Oocyte freezing. Semin Reprod Med 19,221–230.[CrossRef][Web of Science][Medline]
Pourci ML, Mangeot M, Soni T and Lemonnier A (1990) Culture of galactosaemic fibroblasts in the presence of galactose: effect of inosine. J Inherit Metab Dis 13,819–828.[CrossRef][Web of Science][Medline]
Prestoz LL, Couto AS, Shin YS and Petry KG (1997) Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur J Pediatr 156, 116–120.[CrossRef][Web of Science][Medline]
Pru JK and Tilly JL (2001) Programmed cell death in the ovary: insights and future prospects using genetic technologies. Mol Endocrinol 15,845–853.
Qin LQ, Xu JY, Wang PY, Hashi A, Hoshi K and Sato A (2005) Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. Eur J Cancer Prev 14,13–19.[CrossRef][Web of Science][Medline]
Ridel KR, Leslie ND and Gilbert DL (2005) An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol 33,153–161.[CrossRef][Web of Science][Medline]
Risch HA, Jain M, Marrett LD and Howe GR (1994) Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes Control 5,540–548.[CrossRef][Web of Science][Medline]
Roe TF, Hallatt JG, Donnell GN and Ng WG (1971) Childbearing by a galactosemic woman. J Pediatr 78,1026–1030.[CrossRef][Web of Science][Medline]
Rolaki A, Drakakis P, Millingos S, Loutradis D and Makrigiannakis A (2005) Novel trends in follicular development, atresia and corpus luteum regression: a role for apoptosis. Reprod Biomed Online 11,93–103.[Web of Science][Medline]
Roth S, McGuire EJ and Roseman S (1971) Evidence for cell-surface glycosyltransferases. Their potential role in cellular recognition. J Cell Biol 51,536–547.
Russell P, Bannatyne P, Shearman RP, Fraser IS and Corbett P (1982) Premature hypergonadotropic ovarian failure: clinicopathological study of 19 cases. Int J Gynecol Pathol 1,185–201.[Web of Science][Medline]
Sairam MR (1989) Role of carbohydrates in glycoprotein hormone signal transduction. Faseb J 3,1915–1926.[Abstract]
Sato S, Secchi EF, Lizak MJ, Fukase S, Ohta N, Murata M, Tsai JY and Kador PF (1999) Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest Ophthalmol Vis Sci 40,697–704.
Sayle AE, Cooper GS and Savitz DA (1996) Menstrual and reproductive history of mothers of galactosemic children. Fertil Steril 65,534–538.[Web of Science][Medline]
Segal S (1995a) Defective galactosylation in galactosemia: is low cell UDPgalactose an explanation? Eur J Pediatr 154,S65–S71.[Web of Science][Medline]
Segal S (1995b) In utero galactose intoxication in animals. Eur J Pediatr 154,S82–S86.[Web of Science][Medline]
Segal S (1998) Komrower Lecture. Galactosaemia today: the enigma and the challenge. J Inherit Metab Dis 21,455–471.[CrossRef][Web of Science][Medline]
Segal S and Berry G (1995) Disorders of galactose metabolism. In Scriver C, Beaudet A, Sly W and Valle D (eds), The Metabolic and Molecular Basis of Inherited Disease, 7th edn. McGraw-Hill, New York, pp. 967–1000.
Segal S, Wehrli S, Yager C and Reynolds R (2006) Pathways of galactose metabolism by galactosemics: evidence for galactose conversion to hepatic UDPglucose. Mol Genet Metab 87,92–101.[CrossRef][Web of Science][Medline]
Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T and Schneyer AL (1998) Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin’s paracrine signaling from granulosa cells to oocytes. Biol Reprod 59,807–812.
Simoons FJ (1978) The geographic hypothesis and lactose malabsorption. A weighing of the evidence. Am J Dig Dis 23,963–980.[CrossRef][Web of Science][Medline]
Slepak T, Tang M, Addo F and Lai K (2005) Intracellular galactose-1-phosphate accumulation leads to environmental stress response in yeast model. Mol Genet Metab 86,360–371.[CrossRef][Web of Science][Medline]
Song Z, Fu DT, Chan YS, Leung S, Chung SS and Chung SK (2003) Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23,638–647.[CrossRef][Web of Science][Medline]
Steinman B, Gitzelmann R and Zachmann M (1981) Galactosemia: hypergonadotropic hypogonadism found already in prepubertal girls but only in adult males. Eur J Pediatr 135,337.
Stewart MA, Kurien MM, Sherman WR and Cotlier EV (1968) Inositol changes in nerve and lens of galactose fed rats. J Neurochem 15,941–946.[Web of Science][Medline]
Swartz WJ and Mattison DR (1988) Galactose inhibition of ovulation in mice. Fertil Steril 49,522–526.[Web of Science][Medline]
Twigg S, Wallman L and McElduff A (1996) The resistant ovary syndrome in a patient with galactosemia: a clue to the natural history of ovarian failure. J Clin Endocrinol Metab 81,1329–1331.[CrossRef][Web of Science][Medline]
Tyfield LA (2000) Galactosaemia and allelic variation at the galactose-1-phosphate uridyltransferase gene: a complex relationship between genotype and phenotype. Eur J Pediatr 159,S204–S207.[Medline]
Van der Elst J (2003) Oocyte freezing: here to stay? Hum Reprod Update 9,463–470.
Vaskivuo TE and Tapanainen JS (2003) Apoptosis in the human ovary. Reprod Biomed Online 6,24–35.[Medline]
Vitt UA and Hsueh AJ (2001) Stage-dependent role of growth differentiation factor-9 in ovarian follicle development. Mol Cell Endocrinol 183,171–177.[CrossRef][Web of Science][Medline]
Waggoner DD, Buist NR and Donnell GN (1990) Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 13,802–818.[CrossRef][Web of Science][Medline]
Walter JH, Collins JE and Leonard JV (1999) Recommendations for the management of galactosaemia. UK Galactosaemia Steering Group. Arch Dis Child 80,93–96.
Wang ZJ, Berry GT, Dreha SF, Zhao H, Segal S and Zimmerman RA (2001) Proton magnetic resonance spectroscopy of brain metabolites in galactosemia. Ann Neurol 50,266–269.[CrossRef][Web of Science][Medline]
Webb PM, Bain CJ, Purdie DM, Harvey PW and Green A (1998) Milk consumption, galactose metabolism and ovarian cancer (Australia). Cancer Causes Control 9,637–644.[CrossRef][Web of Science][Medline]
Wells WW, Pittman TA, Wells HJ and Egan TJ (1965) The isolation and identification of galactitol from the brains of galactosemia patients. J Biol Chem 240,1002–1004.
Xu YK, Ng WG, Kaufman FR, Lobo RA and Donnell GN (1989) Galactose metabolism in human ovarian tissue. Pediatr Res 25,151–155.[Web of Science][Medline]
Yokoyama T, Sasaki H, Giblin FJ and Reddy VN (1994) A physiological level of ascorbate inhibits galactose cataract in guinea pigs by decreasing polyol accumulation in the lens epithelium: a dehydroascorbate-linked mechanism. Exp Eye Res 58,207–218.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M.E. Rubio-Gozalbo, C.S. Gubbels, J.A. Bakker, P.P.C.A. Menheere, W.K.W.H. Wodzig, and J.A. Land Gonadal function in male and female patients with classic galactosemia Hum. Reprod. Update, September 30, 2009; (2009) dmp038v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ESHRE Capri Workshop Group Genetic aspects of female reproduction Hum. Reprod. Update, April 2, 2008; (2008) dmn009v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Halperin, S. Y. Devi, S. Elizur, C. Stocco, A. Shehu, D. Rebourcet, T. G. Unterman, N. D. Leslie, J. Le, N. Binart, et al. Prolactin Signaling through the Short Form of Its Receptor Represses Forkhead Transcription Factor FOXO3 and Its Target Gene Galt Causing a Severe Ovarian Defect Mol. Endocrinol., February 1, 2008; 22(2): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. H. Knauff, R. Richardus, M. J. Eijkemans, F. J. Broekmans, F. J. de Jong, B. C. J. M. Fauser, and A. M. Bosch Heterozygosity for the Classical Galactosemia Mutation Does Not Affect Ovarian Reserve and Menopausal Age Reproductive Sciences, December 1, 2007; 14(8): 780 - 785. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||